199 related articles for article (PubMed ID: 12562215)
1. Genetic variation of human UDP-glucuronosyltransferase: implications in disease and drug glucuronidation.
Burchell B
Am J Pharmacogenomics; 2003; 3(1):37-52. PubMed ID: 12562215
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance.
Mackenzie PI; Miners JO; McKinnon RA
Clin Chem Lab Med; 2000 Sep; 38(9):889-92. PubMed ID: 11097345
[TBL] [Abstract][Full Text] [Related]
3. Drug glucuronidation by human renal UDP-glucuronosyltransferases.
McGurk KA; Brierley CH; Burchell B
Biochem Pharmacol; 1998 Apr; 55(7):1005-12. PubMed ID: 9605424
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional regulation of human UDP-glucuronosyltransferase genes.
Hu DG; Meech R; McKinnon RA; Mackenzie PI
Drug Metab Rev; 2014 Nov; 46(4):421-58. PubMed ID: 25336387
[TBL] [Abstract][Full Text] [Related]
5. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.
Stingl JC; Bartels H; Viviani R; Lehmann ML; Brockmöller J
Pharmacol Ther; 2014 Jan; 141(1):92-116. PubMed ID: 24076267
[TBL] [Abstract][Full Text] [Related]
6. Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases.
Burchell B; Soars M; Monaghan G; Cassidy A; Smith D; Ethell B
Toxicol Lett; 2000 Mar; 112-113():333-40. PubMed ID: 10720749
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes.
Guillemette C
Pharmacogenomics J; 2003; 3(3):136-58. PubMed ID: 12815363
[TBL] [Abstract][Full Text] [Related]
8. Effect of common exon variant (p.P364L) on drug glucuronidation by the human UDP-glucuronosyltransferase 1 family.
Mimura Y; Maruo Y; Ohta Y; Sato H; Takeuchi Y
Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):486-93. PubMed ID: 21726413
[TBL] [Abstract][Full Text] [Related]
9. N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.
Kaivosaari S; Finel M; Koskinen M
Xenobiotica; 2011 Aug; 41(8):652-69. PubMed ID: 21434773
[TBL] [Abstract][Full Text] [Related]
10. UGT pharmacogenomics: implications for cancer risk and cancer therapeutics.
Desai AA; Innocenti F; Ratain MJ
Pharmacogenetics; 2003 Aug; 13(8):517-23. PubMed ID: 12893990
[TBL] [Abstract][Full Text] [Related]
11. Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation.
Burchell B; Coughtrie MW
Environ Health Perspect; 1997 Jun; 105 Suppl 4(Suppl 4):739-47. PubMed ID: 9255555
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications.
Guillemette C; Lévesque É; Rouleau M
Clin Pharmacol Ther; 2014 Sep; 96(3):324-39. PubMed ID: 24922307
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.
Miners JO; McKinnon RA; Mackenzie PI
Toxicology; 2002 Dec; 181-182():453-6. PubMed ID: 12505351
[TBL] [Abstract][Full Text] [Related]
14. Use of cloned and expressed human liver UDP-glucuronosyltransferases for analysis of drug glucuronide formation and assessment of drug toxicity.
Burchell B; Ebner T; Baird S; Bin Senafi S; Clarke D; Brierley C; Sutherland L
Environ Health Perspect; 1994 Nov; 102 Suppl 9(Suppl 9):19-23. PubMed ID: 7698078
[TBL] [Abstract][Full Text] [Related]
15. UDP-glucuronosyltransferases and clinical drug-drug interactions.
Kiang TK; Ensom MH; Chang TK
Pharmacol Ther; 2005 Apr; 106(1):97-132. PubMed ID: 15781124
[TBL] [Abstract][Full Text] [Related]
16. Expression of UDP-glucuronosyltransferase 1A6 isoform in Caco-2 cells stimulated with lipopolysaccharide.
Panaro MA; Cavallo P; Acquafredda A; Cianciulli A; Calvello R; Mitolo V
Innate Immun; 2010 Oct; 16(5):302-9. PubMed ID: 19710100
[TBL] [Abstract][Full Text] [Related]
17. Characterization of UDP-glucuronosyltransferases (UGTS) involved in the metabolism of troglitazone in rats and humans.
Yoshigae Y; Konno K; Takasaki W; Ikeda T
J Toxicol Sci; 2000 Dec; 25(5):433-41. PubMed ID: 11201174
[TBL] [Abstract][Full Text] [Related]
18. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential.
Miners JO; Mackenzie PI; Knights KM
Drug Metab Rev; 2010 Feb; 42(1):196-208. PubMed ID: 19795925
[TBL] [Abstract][Full Text] [Related]
19. Glucuronidation in humans. Pharmacogenetic and developmental aspects.
de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
Clin Pharmacokinet; 1999 Jun; 36(6):439-52. PubMed ID: 10427468
[TBL] [Abstract][Full Text] [Related]
20. UDP-glucuronosyltransferases.
King CD; Rios GR; Green MD; Tephly TR
Curr Drug Metab; 2000 Sep; 1(2):143-61. PubMed ID: 11465080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
